Due to a constantly growing competition among organizations and higher customer expectations, in the course of the last decades companies started to realize the need for supply chain collaboration (SCC). However, setting up a coalition is often challenging for collaborative parties. One major challenge for the implementation and success of a collaboration is a fair allocation method, which is accepted by and satisfies all collaborative parties. Although researchers already outlined the importance of the parties' acceptance of the gain sharing method, until now the actual acceptance levels of gain sharing methods have not been investigated. This paper fills this gap by investigating the acceptance levels of selected gain sharing methods in vertical three-echelon SCCs in the Dutch fast moving consumer goods (FMCG) industry. In addition, the influence of behavioural decision-making aspects on the acceptance of allocation methods is observed in order to explain the cause of the acceptance or rejection of the gain sharing method. Results indicate that the acceptance of a gain sharing method depends on the information availability and cognitive biases. Furthermore, due to a different influence of available information and varying cognitive biases, no allocation method is accepted by all collaborative parties. Practical implications include to provide each party individually all relevant information to increase the parties' acceptance and to apply debiasing techniques to make the decisions more predictable.
Cytomegalovirus (CMV) represents one of the most common infectious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, a common diagnostic test used to stratify the risk for CMV infection in allo-HSCT recipients is the qualitative CMV serology of donor and recipient. A positive serostatus of the recipient is the most important risk factor for CMV reactivation and associated with reduced overall survival post-transplantation (TX). Direct and indirect effects of CMV are involved in the poorer survival outcome. The present study investigated if the quantitative interpretation of anti-CMV IgG before allo-HSCT might serve as a novel parameter for the identification of patients at risk for CMV reactivation and worse outcome post-TX. For this purpose, a cohort of 440 allo-HSCT recipients over a period of 10 years was retrospectively analyzed. Our findings indicated that patients with high CMV IgG pre-allo-HSCT had a higher risk to develop CMV reactivation, including clinically relevant infections, and a worse prognosis 36 months post-allo-HSCT as compared to recipients with low CMV IgG values. In the letermovir (LMV) era, this group of patients might benefit from a closer CMV monitoring, and hence, earlier intervention if needed, especially after discontinuation of prophylaxis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.